Literature DB >> 36029405

Post-translational Modifications in Parkinson's Disease.

André Saraiva Leão Marcelo Antunes1.   

Abstract

Parkinson's disease (PD) is a complex neurodegenerative disorder characterised by progressive degeneration of the dopaminergic neurons in the substantia nigra leading to severe motor complications. The etiology of the disease is unknown with its sporadic form accounting for 90% of cases. To date, over 20 genes have been identified as the cause of the inherited form of PD, many of them linked to the protein alpha-synuclein and mitochondrial function. Post-translational modifications of proteins allow cells to dynamically control signalling networks and diversify protein functions. This chapter will discuss briefly the main types of post-translational modifications, how to study them and how they affect proteins involved in PD.
© 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  Mass spectrometry; Parkinson's disease; Post translation modifications

Mesh:

Substances:

Year:  2022        PMID: 36029405     DOI: 10.1007/978-3-031-05460-0_6

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   3.650


  49 in total

Review 1.  Proteomic analysis of post-translational modifications.

Authors:  Matthias Mann; Ole N Jensen
Journal:  Nat Biotechnol       Date:  2003-03       Impact factor: 54.908

Review 2.  Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment.

Authors:  K Ray Chaudhuri; Anthony H V Schapira
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

3.  "An essay on the shaking palsy" 200 years old.

Authors:  Wolfgang H Jost; Heinz Reichmann
Journal:  J Neural Transm (Vienna)       Date:  2017-08       Impact factor: 3.575

Review 4.  Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling.

Authors:  T Hunter
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

Review 5.  Epidemiology of Parkinson's disease.

Authors:  Lonneke M L de Lau; Monique M B Breteler
Journal:  Lancet Neurol       Date:  2006-06       Impact factor: 44.182

Review 6.  α-Synuclein in Parkinson's disease.

Authors:  Leonidas Stefanis
Journal:  Cold Spring Harb Perspect Med       Date:  2012-02       Impact factor: 6.915

Review 7.  Glycosylation and other PTMs alterations in neurodegenerative diseases: Current status and future role in neurotrauma.

Authors:  Hussein Abou-Abbass; Hadi Abou-El-Hassan; Hisham Bahmad; Kazem Zibara; Abir Zebian; Rabab Youssef; Joy Ismail; Rui Zhu; Shiyue Zhou; Xue Dong; Mayse Nasser; Marwan Bahmad; Hala Darwish; Yehia Mechref; Firas Kobeissy
Journal:  Electrophoresis       Date:  2016-04-04       Impact factor: 3.535

Review 8.  Mitochondrial dysfunction and oxidative stress in Parkinson's disease.

Authors:  Sudhakar Raja Subramaniam; Marie-Francoise Chesselet
Journal:  Prog Neurobiol       Date:  2013-04-30       Impact factor: 11.685

Review 9.  Proteomics of protein post-translational modifications implicated in neurodegeneration.

Authors:  Ru-Jing Ren; Eric B Dammer; Gang Wang; Nicholas T Seyfried; Allan I Levey
Journal:  Transl Neurodegener       Date:  2014-10-30       Impact factor: 8.014

10.  Parkin disease: a clinicopathologic entity?

Authors:  Karen M Doherty; Laura Silveira-Moriyama; Laura Parkkinen; Daniel G Healy; Michael Farrell; Niccolo E Mencacci; Zeshan Ahmed; Francesca M Brett; John Hardy; Niall Quinn; Timothy J Counihan; Timothy Lynch; Zoe V Fox; Tamas Revesz; Andrew J Lees; Janice L Holton
Journal:  JAMA Neurol       Date:  2013-05       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.